EU Pharmaceutical Strategy Roadmap Seen As Weak On Innovation
Executive Summary
Pharmaceutical industry groups say the European Commission’s Pharmaceutical Strategy Roadmap lacks detail on delivering a faster regulatory process and encouraging competitiveness.
You may also be interested in...
Pharmaceutical Strategy Could Save European ATMP Development
The European Commission’s Pharmaceutical Strategy should end regulatory “carve outs” like the hospital exemptions, and innovate pricing and reimbursement structures, says the Alliance for Regenerative Medicines.
EU Unveils Ambitions To ‘Future-Proof’ Entire Drug Regulatory Framework
Ambitious efforts to make the EU more resilient to future challenges, such as health threats, drug supply problems, scientific advances and growing medicine costs, have taken a step forward with the publication of a roadmap for a wide-ranging Pharmaceutical Strategy to be adopted by the European Commission later in the year.
Scotland Okays Funding For Keytruda and Opdivo For Esophageal Cancer, Among Other Drugs
Immunotherapies for esophageal cancer from BMS and MSD are among the medicines that Scotland’s health technology appraisal body has recommended for use on the National Health system.